A Clinical Perspective: Anti Tau's Treatment in Alzheimer's Disease

Current Alzheimer Research

Volumn 8, Issue 6, 2011, Pages 686-688

  Fuentes, P ^a   Catalan, J ^b  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b International Center for Biomedicine ICC   (Chile)

Author keywords

Alzheimer's disease; Anti tau agents; Disease tratement avenues; Tau pathology and clinical correlations; Tau protein

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; SABELUZOLE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; MICROTUBULE; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; TAU PROTEINS;

EID: 80051741276     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796717221     Document Type: Article

References (23)

1. Maccioni R, Farías G, Morales I, Navarrete L. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 41: 226-231 (2010).
2. Aizenstein H, Nebes R, Saxton J, Price J, Mathis Ch, Tsopelas N, et al. Frquent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (65)11: 1509-1517 (2008).
3. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease:follow-up of randomized, placebo-controlled phase I trial. Lancet 372: 216-23 (2008).
4. Alvarez A, Muñoz JP, Maccioni RB. A cdk5/p35stable complex is involved in the beta-amyloid induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 264: 266-275 (2001).
5. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148 (5): pp. 379-397 (2008).
6. Verhoeff NP. Acetylcholinergic neurotransmission and the betaamyloid cascade: implications for Alzheimer's disease. Expert Rev Neurother 5: 277-284 (2005).
7. Ballard CG, Chalmers KA, Todd C, McKeith IG, ÓBrien JT, Wilcock G, et al. Cholinesterase inhibitors reduce cortical A-beta in dementia with Lewy bodies. Neurology 68: 1726-1729 (2007).
8. Chalmers KA, Wilcock G, Vinters HV, Perry EK, Perry R, Ballard C, et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimés disease. J Neurol 256: 717-720 (2009).
9. Glatz D, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, et al. J Neurochem 96 (3): 635-644 (2006).
10. Farías G, Cornejo A, Jiménez J, Guzmán L, Maccioni RB. Mechanisms of tau selfaggregation and neurotoxicity. Special thematic Issue "Tau protein and Alzheimer's disease. Newparadigms and future challenges" Curr Alzheimer Res 8(6): 608-614 (2011).
11. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid -beta peptides. Nature 423(6938): 435-439 (2003).
12. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, et al. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl) 110 (6): 547-556 (2005).
13. Hampel H, y cols. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled multicenter 10-week study. J Clin Psychiatry 70: 922-931 (2009).
14. Wischik CM, Edwards PK, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by pheniotazines. Proc Natl Acad Sci USA 93: 11213-11218 (1996).
15. Medina DX, Caccamo A, Oddo S. Methilene bluereduces Abeta levels and rescue early cognitive déficits by increasing proteasome activity. Brain Pathol 21: 140-9 (2011).
16. ICAD: Alzheimer's Association International Conference on Alzheimer's Disease (2008).
17. Staff RT, y cols. Tau aggregation inhibitor (TAI) therapy with Rember arrest the trajectory of Rcbf decline in brain regions affected by tau pathology in mild to moderate Alzheimer's disease. Alzheimers Dement 4: T775 (2008).
18. Dickey CA. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117: 648-658 (2007).
19. Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA. Microtubule-stabilizing agents prevent protein accumulationinduced loss of synaptic markers. Eur J Pharmacol 562 (1-2): 20-27 (2007).
20. Zhang B, y cols. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102: 227-231 (2005).
21. Navarrete LP, Pérez P, Morales I, Maccioni RB. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies. Cur Alzheimer Res 8(6): 678-685 (2011).
22. Matsuoka Y, y cols. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325: 146-153 (2008).
23. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Immunotherapy targeting pathologically phosphorylated tau in a tauopathy mouse model. Hot Top Mayo (2009).